Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05218148 | SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma | unknown | Phase 2 | 44 | Aiping ZhouUNKNOWN | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05258266 | A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 76 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05274191 | An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors | unknown | Phase 2 | 60 | Zhongshan Hospital Xiamen UniversityOTHER | 0 | Mar 10, 2022 | clinicaltrials |
| NCT05254665 | A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors | unknown | Phase 2 | 110 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02630368 | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)(METROmaJX) | unknown | Phase 1 / Phase 2 | 197 | Institut BergoniéOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04640246 | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | unknown | Phase 1 / Phase 2 | 60 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | Feb 2, 2022 | clinicaltrials |
| NCT04679038 | A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 222 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT04282278 | Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor | unknown | Phase 2 | 180 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT05119933 | A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation | unknown | Phase 1 / Phase 2 | 55 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05115500 | ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0) | unknown | Phase 2 | 55 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT05097781 | Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients | unknown | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05028478 | A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 164 | Curon Biopharmaceutical (Australia) Co Pty LtdINDUSTRY | 0 | Aug 31, 2021 | clinicaltrials |
| NCT04526470 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | unknown | Phase 1 / Phase 2 | 55 | Seoul National University Bundang HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04237805 | A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 1 / Phase 2 | 280 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04937842 | Microtransplantation for Advanced and Relapsed Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT04337463 | ATG-008 Combined With Toripalimab in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Sichuan UniversityOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT04869475 | Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation | unknown | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04873440 | An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT04832204 | Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases | unknown | Phase 2 | 20 | Beijing HospitalOTHER_GOV | 1 | Apr 5, 2021 | clinicaltrials |
| NCT03704246 | Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors | unknown | Phase 2 | 123 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04761744 | A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers | unknown | Phase 2 | 48 | Korean Cancer Study GroupOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04699643 | FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 80 | EverNov Medicines (Zhuhai Hengqin) Co., LtdINDUSTRY | 1 | Jan 7, 2021 | clinicaltrials |
| NCT04226066 | Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 69 | Tasly Tianjin Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 7, 2020 | clinicaltrials |
| NCT04647838 | Tepotinib in Solid Tumors Harboring MET Alterations | unknown | Phase 2 | 100 | Chungbuk National University HospitalOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT04588324 | Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04569916 | Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors | unknown | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT03544723 | Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. | unknown | Phase 2 | 40 | MultiVir, Inc.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT02638428 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | unknown | Phase 2 | 90 | Samsung Medical CenterOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03168061 | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | unknown | Phase 1 / Phase 2 | 150 | NanoCarrier Co., Ltd.INDUSTRY | 1 | Feb 28, 2020 | clinicaltrials |
| NCT03160833 | A Study of HMPL-453 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 33 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT04179656 | The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor | unknown | Phase 2 | 100 | Tianjin Medical University Second HospitalOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT04151329 | A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor | unknown | Phase 1 / Phase 2 | 72 | Bio-Thera SolutionsINDUSTRY | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04143789 | Evaluation of AP-002 in Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 61 | Altum Pharmaceuticals INCINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT04001569 | AZD8186 and Paclitaxel in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 49 | Seoul National University Bundang HospitalOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT03975036 | Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody | unknown | Phase 2 / Phase 3 | 100 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03940820 | Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT03628131 | Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02787876 | Pegteograstim in Children With Solid Tumors | unknown | Phase 2 | 34 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03615313 | PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor(PAEMCMPAST) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Aug 3, 2018 | clinicaltrials |
| NCT02884479 | An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | unknown | Phase 1 / Phase 2 | 75 | SciClone Pharmaceuticals International (Cayman) Development LimitedINDUSTRY | 1 | Apr 25, 2018 | clinicaltrials |
| NCT03439761 | An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 125 | SciClone PharmaceuticalsINDUSTRY | 1 | Mar 16, 2018 | clinicaltrials |
| NCT03389815 | A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 48 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 4, 2018 | clinicaltrials |
| NCT03182803 | CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT03182816 | CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT03179007 | CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 7, 2017 | clinicaltrials |
| NCT03171220 | Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors(NRT-01) | unknown | Phase 1 / Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT03030001 | PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT02862028 | PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) | unknown | Phase 1 / Phase 2 | 20 | Shanghai International Medical CenterINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT02844881 | Study of Apatinib and MASCT in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | The First People's Hospital of LianyungangOTHER | 1 | Aug 11, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Apr 6, 2022source: clinicaltrials